Our research on drug repurposing for the improved therapy in TP53-mutated AML was awarded.
Jun 20, 2021
Our group is awarded a prize sum of 50.000 SEK from the Cathrine Everts foundation for the study "Drug repurposing to reactivate p53 protein family for improved therapy in TP53-mutated acute myeloid leukemia (AML)".
Link to Cathrine Everts Forskningsstiftelse press release.
Link to Karolinska Institute press release.